Validation and translation of a non-invasive, MR-guided breast cancer therapy

早期局部乳腺癌的治疗已经从高度侵袭性的乳腺癌发展到几十年。 微创、保乳治疗的技术。我们的乳房特异性磁共振引导 聚焦超声系统在高分辨率下非侵入性地将聚焦能量传递到身体深处 图像制导。我们已经取得的技术进步使Poise MRgFUS成为一种几乎准备就绪的非侵入性 局部乳腺疾病的消融治疗。我们已经开发了一套快速的治疗计划方案来 预测超声波束位置和评估潜在波束像差--一种混合磁共振测温方法 监测脂肪和水基组织中的温度，并验证一种新的MRI注册整体 安装组织学技术，将MRI指标与组织病理学分析进行比较。本次R37延期2年 Proposal将在犹他大学经验丰富的学术研究人员和 影像引导疗法的行业调查人员。这一延期将完成并延伸这项重要的工作， 将每个组件集成到ThermoGuideTM中，这是一款临床可用的聚焦超声软件控件 环境。具体地说，我们将：1)使用快速治疗计划技术来评估 乳腺MRgFUS的位相像差矫正技术2)验证了我们的方法的准确性和精密度 混合，聚焦于乳房的体积磁共振测温方法，3)应用我们新的MRI注册整体安装 一种组织学技术，将MRI指标与组织病理学分析、免疫组织化学数据和 4)在一项针对单一侵袭性乳腺的可行性治疗和切除临床试验中对整个方案进行评估 癌症肿瘤。此R37扩展应用程序将完成乳房的验证和翻译 MRgFUS系统在这项建议中，提供了一种令人兴奋的新的图像引导的非侵入性治疗方案 乳腺癌患者。

The treatment of early stage, localized breast cancer has evolved over several decades from highly invasive techniques to minimally invasive, breast-conserving therapies. Our breast-specific magnetic resonance-guided focused ultrasound system non-invasively delivers focused energy deep inside the body under high-resolution image guidance. The technical advances we have made poise MRgFUS as a nearly ready non-invasive ablation treatment for localized breast disease. We have developed a rapid, treatment planning package to predict ultrasound beam placement and assess potential beam aberration, a hybrid MR thermometry method to monitor temperature in both fat and aqueous based tissues and validated a novel MRI-registered whole mount histology technique that compares MRI metrics to histopathological analysis. This R37 2-year extension proposal will continue this work between experienced academic investigators at the University of Utah and industry investigators at Image Guided Therapy. This extension will finish and extend this important work, integrating each component into ThermoGuideTM, a clinic-ready focused ultrasound software control environment. Specifically, we will: 1) Use the rapid treatment planning technique to evaluate the necessity for phase aberration correction techniques in breast MRgFUS, 2) validate the accuracy and precision of our hybrid, breast-focused volumetric MR thermometry method, 3) apply our novel MRI-registered whole mount histology technique that compares MRI metrics to histopathological analysis to immunohistochemistry data and 4) evaluate the entire protocol in a feasibility treat-and-resect clinical trial targeting unifocal invasive breast cancer tumors. This R37 extension application will complete the validation and translation of the breast MRgFUS System in this proposal, providing an exciting new image-guided non-invasive treatment option for breast cancer patients.